AXIM Biotechnologies, Inc. (OTC:AXIM) has announced the engagement of 624 Advisors, owned and managed by Dr. Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch, a preeminent figure in in vitro diagnostics (IVD) and companion diagnostics (CDx), brings more than three decades of global leadership across diagnostics, medical devices, pharmaceuticals, and digital health. This strategic move is expected to enhance AXIM’s technical continuity, regulatory depth, and execution capability at a pivotal stage of the company’s development.
Dr. Touch is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM, as well as the inventor of the world’s first colored contact lens. His career includes former leadership roles as head of Clinical Affairs at Bausch & Lomb and Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (now Syneos Health). As Chief Science Officer of an ophthalmic contract development and manufacturing organization (CDMO), he led the development of several proprietary dry eye disease (DED) products, including the first eye drop targeting the inflammatory cascade through a novel pathway. He also founded 624 Advisors as a product development, regulatory, and quality compliance consultancy.
“This strategic engagement is an important addition to the R&D and regulatory team at AXIM,” said Catalina Valencia, President and CEO of AXIM Biotechnologies. “Dr. Touch uniquely combines inventor-level knowledge of our technology with significant senior level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. His involvement strengthens our regulatory strategy, quality foundation, and clinical execution, while positioning AXIM for efficient global expansion and long-term operational scale.”
AXIM is advancing toward key regulatory and commercial milestones, including upcoming FDA 510(k) submissions, international regulatory expansion, and the establishment of a robust quality and manufacturing infrastructure. Dr. Touch’s advisory role is designed to provide highly qualified support across these areas, reducing reliance on external consultants and accelerating readiness for commercialization and global growth.
Dr. Touch’s background aligns with AXIM’s current efforts and upcoming goals, including inventor-level understanding of lactoferrin and immunoassay diagnostics, deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks, and proven leadership in regulatory affairs, quality systems, clinical development, and manufacturing scale-up. He will also contribute to building a milestone-based product development value proposition.
“I am pleased to work with AXIM at this important stage and to continue advancing technology I originally helped develop,” said Dr. Alan J. Touch. “AXIM is building a strong foundation for market-sensitive and aware regulatory excellence and clinical credibility for its products. I look forward to supporting an excellent and cohesive scientific, marketing and operational team as they advance key submissions, strengthen quality systems, and prepare for long-term manufacturing and commercial success.”
AXIM Biotechnologies develops and commercializes rapid, point-of-care diagnostic tests focused on ocular and systemic health. Its TearScan® platform enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes. For more information, visit www.aximbiotech.com.
